Month: January 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. For immediate release 7 January 2025 Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) — Further to the announcement on 2 January 2025 (the “2.4 Announcement”), the Boards of Poolbeg and HOOKIPA are pleased to confirm that significant HOOKIPA...

Acquisition Supercharges Gilat’s IFC Growth, Establishing a Global Leader in Aviation and High-End Mobility for ESA Applications Expected to Add $120-150 million in 2025 Annual Revenues PETAH TIKVA, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a global leader in satellite networking technology, solutions, and services, today announced that it has successfully closed the acquisition of Stellar Blu Solutions LLC (“Stellar Blu”), a leading US-based provider of next-generation SATCOM terminal solutions. Gilat expects its annual revenues from Stellar Blu to range between $120 and $150 million in 2025, based on Stellar Blu’s robust backlog. In addition, the acquisition is expected to be accretive on non-GAAP results for 2025. Furthermore, the Company estimates that once Stellar Blu...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil Fagron, the leading global player in pharmaceutical compounding is pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron’s commitment to expanding across our key markets whilst adhering to our disciplined acquisition strategy. The combined enterprise value of these two acquisitions is c.€30m and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin. CareFirst Specialty Pharmacy, based in...